Benzinga | Apr 26, 2021 04:03PM EDT

Biodesix Ro Present On SARS-CoV-2 Neutralizing Antibody Testing for Individual Vaccine Response and Commercial Launch Plans May 5

Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced in partnership with GenScript Biotech Corporation, a webinar to present novel data on the rapid detection of total SARS-CoV-2 neutralizing antibodies using cPass(tm) technology. Neutralizing antibodies may specifically block the interaction between the receptor binding protein on SARS-CoV-2, and the host cell's membrane receptor protein, thereby preventing infection of the cell by the virus. The webinar entitled "SARS-CoV-2 Neutralizing Antibody Testing for Vaccine Efficacy Assessment" will be presented by Dr. Laura Peek from Biodesix, and Dr. Sean Taylor from GenScript(r), and is scheduled for 1:00 pm ET on Wednesday May 5, 2021. Participants are encouraged to register here.